Form 4: Pharvaris CMO Peng Lu Reports Tax Withholding Transactions

Chief Medical Officer Peng Lu reported the withholding of 226 shares of Pharvaris N.V. common stock to satisfy tax obligations related to RSU vesting.

Summary

• Peng Lu, Chief Medical Officer of Pharvaris N.V., executed two transactions involving the withholding of shares for tax purposes.
• On May 11, 2026, 109 shares were withheld at a price of $30.09 per share.
• On May 12, 2026, 117 shares were withheld at a price of $29.95 per share.
• Following these transactions, the reporting person maintains a beneficial ownership of 65,857 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are purely administrative and related to tax compliance rather than discretionary trading.

Positives

• The transactions reflect the vesting of restricted stock units, indicating ongoing equity-based compensation alignment for executive leadership.

Negatives

• None; these transactions are routine administrative actions related to tax obligations upon equity vesting.

Risks

• None; this is a standard regulatory disclosure of tax-related share withholding.

Future Outlook

Not applicable; this is a retrospective disclosure of equity transactions.

Industry Context

StockSavvy.ai notes that routine tax withholding filings by executives are standard industry practice and do not typically signal changes in management sentiment or company outlook.

Comparison to Industry Standards

• The transaction structure is consistent with standard executive compensation practices in the biotechnology sector.
• The use of 'sell-to-cover' or share withholding for tax obligations is a common mechanism used by executives at companies like Amgen, Biogen, and other mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transactions represent standard tax compliance for equity compensation.

Next Steps

• No further actions required by the reporting person regarding these specific transactions.

Key Dates

Keywords

Pharvaris, PHVS, Form 4, Insider Trading, Tax Withholding, Equity Vesting